Immuneering CorporationIMRXNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank83
3Y CAGR+5.1%
5Y CAGR+22.9%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
+5.1%/yr
Annual compound
5Y CAGR
+22.9%/yr
Recent deceleration
Percentile
P83
Within normal range
vs 5Y Ago
2.8x
Strong expansion
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$42.05M-12.3%
2024$47.96M+15.2%
2023$41.62M+14.8%
2022$36.27M+36.6%
2021$26.54M+76.9%
2020$15.00M+250.6%
2019$4.28M-